KRS Capital Management’s GSK GSK Stock Holding History

KRS Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-101	Closed	-$5K	–	214
2021 Q4	$5K	Buy	+101	New	+$5.25K	﹤0.01%	356

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

KRS Capital Management's GSK Position: Q1 2022 in Review

KRS Capital Management sold out of GSK (GSK) in Q1 2022, closing a stake of 101 shares — an estimated $5K sold.

KRS Capital Management first reported a position in GSK in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

KRS Capital Management reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
KRS Capital Management sold 101 GSK shares in Q1 2022, an estimated $5K.
KRS Capital Management first reported a position in GSK in Q4 2021 and held it in 1 quarter.
KRS Capital Management's GSK position peaked at $5K in Q4 2021.
929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.